SCHEMBL4283565

SCHEMBL4283565

COc1cc2occ(-c3cc4c(cc3OC)OCO4)c(=O)c2cc1OC

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.51
ACHE P22303 4/20 0.51
RAB9A P51151 4/20 0.51
MAPT P10636 3/20 0.51
NPC1 O15118 3/20 0.51
LMNA P02545 1/20 0.51
CYP3A4 P08684 4/20 0.49
HSD17B10 Q99714 3/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
ALDH1A1 P00352 3/20 0.46
HDAC6 Q9UBN7 1/20 0.46
PTPN1 P18031 1/20 0.46
PPARG P37231 1/20 0.46
KLK7 P49862 1/20 0.45
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
USP2 O75604 1/20 0.44
GLA P06280 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1675988 0.85 RAB9A (0.71) SMN1; SMN2RAB9AMAPTNPC1LMNA
Cuneatin SCHEMBL29818214 0.84 KDM4E (0.67) SMN1; SMN2RAB9AMAPTNPC1LMNA
Glaziovianin A SCHEMBL29402459 0.80 ACHE (0.49) SMN1; SMN2ACHERAB9AMAPTNPC1
SCHEMBL29378746 0.76 MAPT (0.53) SMN1; SMN2RAB9AMAPTNPC1LMNA
SCHEMBL571676 0.76 HDAC6 (0.61) SMN1; SMN2ACHERAB9AMAPTNPC1
SCHEMBL29365787 0.75 RAB9A (0.67) SMN1; SMN2ACHERAB9AMAPTNPC1
SCHEMBL28314002 0.73 NPC1 (0.53) ACHERAB9AMAPTNPC1HSD17B10
SCHEMBL10564937 0.73 RAB9A (0.72) SMN1; SMN2ACHERAB9AMAPTNPC1
Ichthynone SCHEMBL29934702 0.73 BCHE (0.60) SMN1; SMN2MAPTLMNACYP3A4HSD17B10
Ichthynone SCHEMBL9924621 0.73 BCHE (0.60) SMN1; SMN2MAPTLMNACYP3A4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143279-A1 Methods and compositions for treating metabolic disorders PRESIDENT AND FELLOWS OF HARVARD COLLEGE 2009-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090143279-A1 Methods and compositions for treating metabolic disorders PC, PCK2, CS SMN1; SMN2 281/4885ACHE 865/4885RAB9A 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.